Exelixis Inc

Type: Company
Name: Exelixis Inc
Nationality: United States
Web Address: http://www.exelixis.com/
First reported Jul 05 2014 - Updated Jul 05 2014 - 1 reports

Big Pharma Needs Growth: Two Severely Undervalued Companies Ripe for a Takeover

Source: Thinkstock At any given moment, there are literally hundreds of severely undervalued companies that are ripe for takeovers. In this article, I will focus on the pharmaceutical industry, where many investors have borth struck it rich when ... [Published Wall St. Cheat Sheet - Jul 05 2014]
First reported Jul 02 2014 - Updated Jul 02 2014 - 1 reports

Exelixis : Patent Issued for CDK9 as Modifier of the IGF Pathway and Methods of Use

By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Alexandria, Virginia , by NewsRx journalists, a patent by the inventors Maxwell , Mark E . ( Lansdale, PA ); Ollmann, Michael Martin ( Redwood ... [Published 4 Traders - Jul 02 2014]
First reported Jul 01 2014 - Updated Jul 01 2014 - 1 reports

Exelixis Sees Significant Drop in Short Interest (EXEL)

Shares of Exelixis (NASDAQ:EXEL) saw a significant drop in short interest during the month of June. As of June 13th, there was short interest totalling 48,357,190 shares, a drop of 1.5% from the May 30th total of 49,073,148 shares, AmericanBankingNews.com ... [Published American Banking News - Jul 01 2014]
First reported Jun 27 2014 - Updated Jun 27 2014 - 1 reports

Product and Pipeline Analysis of the Global Therapeutic Lipid Modulators Market

Research and Markets (http://www.researchandmarkets.com/research/vkj9fb/product_and) has announced the addition of the "" report to their offering. Dyslipidemia exists in many forms and is prevalent in developed regions. Although many patients with moderately ... [Published Individual.com - Jun 27 2014]
First reported Jun 19 2014 - Updated Jun 19 2014 - 1 reports

Two Cancer Stocks Take Shots On Goal: Echo He

Summary People attending ASCO are looking for specific, targeted treatment solutions, and for data that show significant improvements in efficacy over previously approved drugs. Generalists tend to chase momentum. If you're looking at a changed mood, ... [Published Seeking Alpha - Jun 19 2014]
First reported Jun 13 2014 - Updated Jun 13 2014 - 1 reports

3/A - EXELIXIS, INC. (0000939767) (Issuer)

Document Format FilesSeq Description Document Type Size 1 rrd411675.html 3/A 1 rrd411675.xml 3/A 2499 2 POWER OF ATTORNEY rrd370743_419838.htm EX-24.POA 3720 Complete submission text file 0001181431-14-023840.txt 7729 ... [Published SEC - Jun 13 2014]
Entities: Exelixis Inc, HTML
First reported Jun 12 2014 - Updated Jun 12 2014 - 1 reports

5 Stocks Under $10 Set to Soar Higher

DELAFIELD, Wis. (Stockpickr) -- There isn't a day that goes by on Wall Street when certain stocks trading for $10 a share or less don't experience massive spikes higher. Traders savvy enough to follow the low-priced names and trade them with discipline ... [Published The Street Latest - Jun 12 2014]
First reported Jun 10 2014 - Updated Jun 10 2014 - 1 reports

Exelixis (EXEL) CEO Michael Morrissey Presents at Goldman Sachs 35th Annual Global Healthcare Conference (Transcript)

Exelixis, Inc. ( EXEL ) Goldman Sachs 35th Annual Global Healthcare Conference June 10, 2014 12:20 PM ETTerence Flynn - Goldman SachsOkay, great. Well thanks for joining us everybody. I am Terence Flynn, one of the biotech analysts here at Goldman Sachs ... [Published Seeking Alpha - Jun 10 2014]
First reported Jun 10 2014 - Updated Jun 10 2014 - 1 reports

Conferences/Events Scheduled for Week of Jun. 9th to Jun. 13th

Morgan Stanley Global Natural Resources Conference – Jun. 9 to Jun. 10 - Barcelona Companies to participate: Hecla Mining Company ...Related Stocks:ACTIVISION BLIZZARD AETNA, Inc. AGIOS PHARM AIRGAS, Inc. AM CAPITAL AGN REIT AMERICAN EXPRESS COMPANY AMTRUST ... [Published Fat Pitch Financials - Jun 10 2014]
First reported Jun 03 2014 - Updated Jun 04 2014 - 4 reports

Exelixis to Present at the Goldman Sachs 35th Annual Global Healthcare Conference on June 10

. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s president and chief executive officer, will provide an overview of the company at the Goldman Sachs 35thThe presentation will be webcast live and may be accessed via the Event ... [Published Cincinnati.com - Jun 03 2014]
First reported May 01 2014 - Updated May 01 2014 - 3 reports

Exelixis Announces First Quarter 2014 Financial Results

SOUTH SAN FRANCISCO, Calif.--(EON: Enhanced Online News)--Exelixis, Inc. (Nasdaq:EXEL) today reported financial results for the quarter ended March 31, 2014. Q1 2014 Highlights and Recent Events The European Commission approved COMETRIQ® (cabozantinib) ... [Published EON Business - May 01 2014]
First reported Apr 21 2014 - Updated Apr 22 2014 - 2 reports

Exelixis to Release First Quarter 2014 Financial Results on Thursday May 1 2014

- Conference Call and Webcast to Follow -Related Biotechnology, Pharmaceutical and Healthcare NewsExelixis, Inc. (NASDAQ: EXEL) will release its first quarter 2014financial results on Thursday, May 1, 2014 after the markets close. Theannouncement will ... [Published BioPortfolio - Apr 21 2014]

Quotes

In addition to obtaining background information on this patent, NewsRx editors also obtained the inventors' summary information for this patent: "We have discovered genes that modify the IGF pathway in Drosophila cells, and identified their human orthologs, hereinafter referred to as cyclin dependent kinase 9 (CDK9). The invention provides methods for utilizing these IGF modifier genes and polypeptides to identify CDK9-modulating agents that are candidate therapeutic agents that can be used in the treatment of disorders associated with defective or impaired IGF function and/or CDK9 function. Preferred CDK9-modulating agents specifically bind to CDK9 polypeptides and restore IGF function. Other preferred CDK9-modulating agents are nucleic acid modulators such as antisense oligomers and RNAi that repress CDK9 gene expression or product activity by, for example, binding to and inhibiting the respective nucleic acid (i e. DNA or mRNA)."
According to Erickson, "Steve's history in the biotech industry reaches back over 40 years. He's witnessed and been involved in the formation and growth of biotech's earliest companies. The Life Sciences Foundation has greatly benefited from his perspective and passion for the biotech industry."
"Hepatocellular carcinoma is a huge challenge to treat. Patients with advanced HCC have a median overall survival of less than 1 year, largely because of the absence of effective therapies. It's really humbling" Dr. Zhu told Medscape Medical News

More Content

All (112) | News (51) | Reports (0) | Blogs (58) | Audio/Video (0) | Fact Sheets (0) | Press Releases (3)
sort by: Date | Relevance
Global cos reluctant to introduce latest cancer... [Published PharmaBiz - Jul 09 2014]
People in the News (7/06/14): Appointments and ... [Published Philanthropy News Digest - Jul 06 2014]
Big Pharma Needs Growth: Two Severely Undervalu... [Published Wall St. Cheat Sheet - Jul 05 2014]
West Coast Biotech Roundup: Seragon, Ambrx, Pre... [Published BioPortfolio - Jul 03 2014]
Exelixis : Patent Issued for CDK9 as Modifier o... [Published 4 Traders - Jul 02 2014]
Life Sciences Foundation Appoints Carl Feldbaum... [Published MoneyShow.com - Jul 02 2014]
Everolimus Fails to Improve Overall Survival in... [Published General Medicine eJournal - Jul 01 2014]
Exelixis Sees Significant Drop in Short Interes... [Published American Banking News - Jul 01 2014]
Product and Pipeline Analysis of the Global The... [Published Individual.com - Jun 27 2014]
Eisai files first marketing application for len... [Published Pharma Letter - Jun 27 2014]
West Coast Biotech Roundup: Affymax, K2, Roche/... [Published BioPortfolio - Jun 26 2014]
Zafgen Supersizes Its Obesity-Focused IPO: An E... [Published Forbes.com - Jun 25 2014]
Two Cancer Stocks Take Shots On Goal: Echo He [Published Seeking Alpha - Jun 19 2014]
3/A - EXELIXIS, INC. (0000939767) (Issuer) [Published SEC - Jun 13 2014]
5 Stocks Under $10 Set to Soar Higher [Published The Street Latest - Jun 12 2014]
West Coast Biotech Roundup: Dendreon, Venter, O... [Published BioPortfolio - Jun 12 2014]
Exelixis (EXEL) CEO Michael Morrissey Presents ... [Published Seeking Alpha - Jun 10 2014]
Dendreon's CEO Exits: Is this the Beginning of ... [Published Motley Fool - Jun 10 2014]
"Breast Cancer - Pipeline Review, H1 2014" Is N... [Published SBWire - Jun 10 2014]
Conferences/Events Scheduled for Week of Jun. 9... [Published Fat Pitch Financials - Jun 10 2014]
West Coast Biotech Roundup: NanoString, Sequeno... [Published BioPortfolio - Jun 06 2014]
Exelixis : to Speak at the Goldman Sachs 35th A... [Published 4 Traders - Jun 06 2014]
Exelixis to Present at the Goldman Sachs 35th A... [Published Cincinnati.com - Jun 03 2014]
Exelixis to Present at the Goldman Sachs 35th A... [Published Investing.com - Jun 03 2014]
EXELIXIS : to Present at the Goldman Sachs 35th... [Published 4 Traders - Jun 03 2014]
Exelixis to Present at the Goldman Sachs 35th A... [Published Business Wire Health News - Jun 03 2014]
Early Trial of Cabozantinib and Abiraterone Sho... [Published Cancernetwork.com - Jun 02 2014]
Exelixis Sees Significant Growth in Short Inter... [Published American Banking News - Jun 02 2014]
Studies Reveal Potential New Targeted Therapies... [Published Newswise - Jun 01 2014]
Form 8-K: Exelixis Files Current Report [Published HighBeam Research - Jun 01 2014]
1 2 3 4
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Big Pharma Needs Growth: Two Severely Undervalu... [Published Wall St. Cheat Sheet - Jul 05 2014]
Source: Thinkstock At any given moment, there are literally hundreds of severely undervalued companies that are ripe for takeovers. In this article, I will focus on the pharmaceutical industry, where many investors have borth struck it rich when ...
Exelixis to Present at the Goldman Sachs 35th A... [Published Business Wire Health News - Jun 03 2014]
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s president and chief executive officer, will provide an overview of the company at the Goldman Sachs 35th Annual ...
Cabozantinib and Cobimetinib to Be Featured in ... [Published Business Wire Health News - May 14 2014]
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced that cabozantinib and cobimetinib will be the subject of ten presentations at the upcoming 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO). ...
BioNews – 05/07/14 [Published eClinical Trends - May 07 2014]
Top News HeadlineCompanyType Spin-Out Date Confirmed: Theravance, Inc. (THRX) Eyes June 2 Split Into Drug, Royalties Companies TheravanceCompany Structure British PM wants more Pfizer promises, but pharma's merger vows are fleeting PfizerJobs DrugDev ...
Exelixis Announces Presentation of Final Phase ... [Published Business Wire Health News - May 07 2014]
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) today announced final results from BRIM7, an ongoing phase 1b clinical trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group (SIX: RO, ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Technical Data on Biotech Stocks -- Research on... [Published Financial Services - May 06 2014]
Cometriq® approved in Europe for the treatment ... [Published GlobeNewswire: Acquisitions News - Mar 25 2014]
Pre-Market Pulse - Health Care Sector Stocks --... [Published Financial Services - Mar 24 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.